Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms

Al-Ghazo, Mohammed A.; Ghalayini, Ibrahim Fathi; Al-Azab, Rami; Hani, Osama Bani; Matani, Yousef S.; Haddad, Yazan

doi:10.5213/inj.2011.15.1.48

Cited by 49 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we pooled the data of comparison between OAB‐wet and OAB‐dry patients, it showed OAB‐wet group had a higher urinary NGF/Cr level than OAB‐dry group. Because OAB‐wet patients are more related to detrusor overactivity (DO), it is postulated that OAB patients with DO could have higher urinary levels of NGF/Cr than those without DO. Above‐mentioned results suggested that NGF might have a potential to be a biomarker for diagnosis and evaluation of OAB.…”

Section: Discussionmentioning

confidence: 99%

Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis

Wei¹,

Zhang

Ruth³

2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

A total of 17 published studies were included in this meta-analysis. Among the studies considered, patients with OAB had a significant higher baseline urinary NGF/Cr (NGF normalized to urine creatinine) level compared to those of controls (SMD = 0.74, 95%CI = 0.43-1.04, P < 0.00001). After treatment, the level of NGF/Cr decreased significantly in OAB group. However, there was no significant difference between patients with IC (interstitial cystitis)/PBS (painful bladder syndrome) and patients with overactive bladder (OAB) with regard to the urinary NGF/Cr level (SMD = 0.18, 95%CI = -0.06 to 0.41, P = 0.14). There was a statistically significant heterogeneity among included studies (P < 0.00001, I = 85%). No obvious evidence of significant publication bias was detected. In conclusion, this meta-analysis indicates that urine NGF/Cr may be a useful biomarker for OAB in the future. Because of lack of specificity, it seems that NGF/Cr cannot be used as a biomarker for OAB at present. Nevertheless, combined with other biological indicators may improve its specificity in diagnosis. More high quality studies that control the compounding factors strictly should be conducted in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis

Wei¹,

Zhang

Ruth³

2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…The extent to which the use of UDS prior to surgery correlates with treatment outcome has long been controversial. In addition, up to 40% of women with clinical symptoms of OAB and UUI will not demonstrate overactivity on UDS . A Cochrane review from 2002 studied the impact of UDS and found insufficient data to support or refute the importance of urodynamics testing prior to surgical intervention .…”

Section: Discussionmentioning

confidence: 99%

Trends in surgical management and pre‐operative urodynamics in female medicare beneficiaries with mixed incontinence

Chughtai

Hauser

Anger

et al. 2015

Neurourology and Urodynamics

View full text Add to dashboard Cite

Utilization of UDS increased during the study period, from 38.4% to 74.0% prior to initial surgical intervention, and from 28.6% to 62.5% preceding re-intervention. Sling surgery (63.0%) and injectable bulking agents (28.0%) were the most common surgical treatments adopted, followed by sacral nerve stimulation (SNS) (4.8%) and Burch (4.0%) procedures. Re-intervention was performed in 4.0% of patients initially treated with sling procedures and 21.3% of patients treated with bulking agents, the majority of whom (51.7% and 76.3%, respectively) underwent injection of a bulking agent. Risk of re-intervention was not different among those who did or did not receive urodynamic tests prior to the initial procedure (8.5% vs. 9.3%) CONCLUSIONS: Sling and bulk agents are the most common treatment for MUI. Preoperative urodynamic testing was not related to risk of re-intervention following surgery for mixed urinary incontinence in this cohort. Neurourol. Urodynam. 36:422-425, 2017. © 2015 Wiley Periodicals, Inc.

show abstract

“…There was a better correlation in results between OAB symptoms and the urodynamic diagnosis of DO in men than in women, more so in OAB wet than in OAB dry. 17 Pharmacotherapies that target the prostate often fail to alleviate OAB symptoms, and may not be the most appropriate therapy for men with storage LUTS. Multiple studies have suggested that antimuscarinics alone or in combination with alpha1-receptor antagonists improve OAB symptoms in men with and without BOO.…”

Section: Male Luts and Oab E Backgroundmentioning

confidence: 99%

Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder

2015

View full text Add to dashboard Cite

Keywords: benign prostatic hyperplasia guideline lower urinary tract symptoms overactive bladder a b s t r a c tThe purpose of this guideline is to direct urologists and patients regarding how to identify overactive bladder (OAB) in male patients with lower urinary tract symptoms (LUTS) and to make an accurate diagnosis and establish treatment goals to improve the patients' quality of life (QoL). LUTS are commonly divided into storage, voiding, and postmicturition symptoms, and are highly prevalent in elderly men. LUTS can result from a complex interplay of pathophysiologic features that can include bladder dysfunction and bladder outlet dysfunction such as benign prostatic obstruction (BPO) or poor relaxation of the urethral sphincter. Diagnosis of OAB in male LUTS leads to accurate diagnosis of pure OAB and bladder outlet-related OAB, and appropriate treatment in men with residual storage symptoms after treatment for LUTS. PurposeThe purpose of this guideline is to direct urologists and patients regarding how to identify overactive bladder (OAB) from male patients with lower urinary tract symptoms (LUTS) and to make an accurate diagnosis and establish treatment goals to improve patients' quality of life (QoL). Male LUTS and OAB e background2.1. LUTS are highly prevalent among older men and have a negative impact on health-related QoL (HRQoL). (LE 1a, Grade A) OAB is associated with medical diseases such as diabetes and congestive heart failure. (LE 2b, Grade B) OAB and urinary incontinence symptom severity progress dynamically and are also sustained over time. (LE 2a, Grade B) OAB is a clinical diagnosis defined by the International Continence Society as the presence of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of a urinary tract infection or other obvious pathology". 1 OAB symptoms can be bothersome and can negatively affect HRQoL, increase anxiety and depression, and increase health care usage. The strongest predictor of OAB-associated bother was urinary urgency. 2 OAB also adversely affects sexuality in both men and women. 3 OAB is common in older adults and is associated with substantial impairment in mental health and HRQoL, but rates of treatment seeking behavior are low. 4 Urgency is the core symptom for the presence of OAB. It has been estimated that 10e16% of the population in the world has the OAB condition. 5 However, although an urgency severity scale has been suggested, the grade of urgency is reported subjectively by the patients; therefore, there could be a wide variation among different grades of the reported urgency severity. 6 The incidence of LUTS, including OAB in men, increases with age. Frequent comorbidity with potential prostatic disease adds complexity to the management of male LUTS. 7 In addition, patients with congestive heart failure had more storage urinary symptoms suggestive of OAB than did the age-matched controls. 8 Patients with type 2 diabetes mellitus present more OAB symptoms such as urgen...

show abstract

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms

Cited by 49 publications

References 13 publications

Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis

Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis

Trends in surgical management and pre‐operative urodynamics in female medicare beneficiaries with mixed incontinence

Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder

Contact Info

Product

Resources

About